All times are listed in CEST (Central European Summer Time)

Displaying One Session

View
Munich Hall ESMO Colloquium

ESMO Colloquium supported by Lilly - Optimising risk prediction, management and compliance for patients with early HR+ HER2- breast cancer: The start of a journey (ID 33)

Date
Tue, 03.05.2022
Time
18:00 - 19:35
Room
Munich Hall
Chairs
Session Type
ESMO Colloquium
ESMO Colloquium supported by Lilly - Optimising risk prediction, management and compliance for patients with early HR+ HER2- breast cancer: The start of a journey (ID 33)

Introduction (ID 328)

Lecture Time
18:00 - 18:10
Speakers
Authors
Session Name
ESMO Colloquium supported by Lilly - Optimising risk prediction, management and compliance for patients with early HR+ HER2- breast cancer: The start of a journey (ID 33)
Room
Munich Hall
Date
Tue, 03.05.2022
Time
18:00 - 19:35
ESMO Colloquium supported by Lilly - Optimising risk prediction, management and compliance for patients with early HR+ HER2- breast cancer: The start of a journey (ID 33)

Risk prediction for patients with early HR+, HER2-, node-positive breast cancer: How to best integrate clinicopathologic and genomic tests? (ID 329)

Lecture Time
18:10 - 18:25
Speakers
Authors
Session Name
ESMO Colloquium supported by Lilly - Optimising risk prediction, management and compliance for patients with early HR+ HER2- breast cancer: The start of a journey (ID 33)
Room
Munich Hall
Date
Tue, 03.05.2022
Time
18:00 - 19:35
ESMO Colloquium supported by Lilly - Optimising risk prediction, management and compliance for patients with early HR+ HER2- breast cancer: The start of a journey (ID 33)

An overview of the adjuvant trials evaluating CDK4/6 inhibitors in early HR+ HER2- breast cancer (ID 330)

Lecture Time
18:25 - 18:40
Speakers
Authors
Session Name
ESMO Colloquium supported by Lilly - Optimising risk prediction, management and compliance for patients with early HR+ HER2- breast cancer: The start of a journey (ID 33)
Room
Munich Hall
Date
Tue, 03.05.2022
Time
18:00 - 19:35
ESMO Colloquium supported by Lilly - Optimising risk prediction, management and compliance for patients with early HR+ HER2- breast cancer: The start of a journey (ID 33)

A case on localised HR+, HER- breast cancer treated with adjuvant therapy/abemaciclib (ID 482)

Lecture Time
18:40 - 18:50
Speakers
Authors
Session Name
ESMO Colloquium supported by Lilly - Optimising risk prediction, management and compliance for patients with early HR+ HER2- breast cancer: The start of a journey (ID 33)
Room
Munich Hall
Date
Tue, 03.05.2022
Time
18:00 - 19:35
ESMO Colloquium supported by Lilly - Optimising risk prediction, management and compliance for patients with early HR+ HER2- breast cancer: The start of a journey (ID 33)

Shaping an emerging continuum of care for patients with HR+, HER2- breast cancer: Which patients to select, from localized to recurrent disease (ID 332)

Lecture Time
18:50 - 19:05
Speakers
Authors
Session Name
ESMO Colloquium supported by Lilly - Optimising risk prediction, management and compliance for patients with early HR+ HER2- breast cancer: The start of a journey (ID 33)
Room
Munich Hall
Date
Tue, 03.05.2022
Time
18:00 - 19:35
ESMO Colloquium supported by Lilly - Optimising risk prediction, management and compliance for patients with early HR+ HER2- breast cancer: The start of a journey (ID 33)

Shaping an emerging continuum of care for patients with HR+, HER2- breast cancer: A case on metastatic breast cancer treated with CDK4/6 inhibitors (ID 483)

Lecture Time
19:05 - 19:15
Speakers
Authors
Session Name
ESMO Colloquium supported by Lilly - Optimising risk prediction, management and compliance for patients with early HR+ HER2- breast cancer: The start of a journey (ID 33)
Room
Munich Hall
Date
Tue, 03.05.2022
Time
18:00 - 19:35
ESMO Colloquium supported by Lilly - Optimising risk prediction, management and compliance for patients with early HR+ HER2- breast cancer: The start of a journey (ID 33)

Q&A and discussion (ID 333)

Lecture Time
19:15 - 19:30
Speakers
Authors
Session Name
ESMO Colloquium supported by Lilly - Optimising risk prediction, management and compliance for patients with early HR+ HER2- breast cancer: The start of a journey (ID 33)
Room
Munich Hall
Date
Tue, 03.05.2022
Time
18:00 - 19:35
ESMO Colloquium supported by Lilly - Optimising risk prediction, management and compliance for patients with early HR+ HER2- breast cancer: The start of a journey (ID 33)

Concluding remarks (ID 334)

Lecture Time
19:30 - 19:35
Speakers
Authors
Session Name
ESMO Colloquium supported by Lilly - Optimising risk prediction, management and compliance for patients with early HR+ HER2- breast cancer: The start of a journey (ID 33)
Room
Munich Hall
Date
Tue, 03.05.2022
Time
18:00 - 19:35